Literature DB >> 30957173

Serum Free Light Chain Assay in Monoclonal Gammopathic Manifestations.

Won S Lee1, Gurmukh Singh1.   

Abstract

BACKGROUND: Serum free light chain assay is used in the diagnosis and monitoring of monoclonal gammopathic manifestations. For the kappa (κ)/lambda (λ) ratio, there is a 36% false-positive rate in patients without monoclonal gammopathic manifestations and a 30% false-negative rate in patients with monoclonal gammopathic manifestations. This study was undertaken to address the higher false-negative rate in λ chain-associated monoclonal lesions.
METHODS: Results of serum protein electrophoresis, serum immunofixation electrophoresis, and serum free light chain assays were reviewed retrospectively. The results for serum free light chains in cases of intact immunoglobulin monoclonal gammopathic manifestations only were analyzed.
RESULTS: Concentrations of involved serum free light chains were significantly higher in κ chain-associated lesions than in λ chain-associated lesions. The concentration of uninvolved light chains was significantly higher in λ chain-associated lesions.
CONCLUSIONS: κ light chains are present in significantly greater abundance than are λ chains in their respective monoclonal lesions. Moreover, κ and λ light-chain levels are not comparable for similar quantitative levels of monoclonal immunoglobulins. The findings warrant a reconsideration of the role of serum free light chain concentrations and involved to uninvolved serum free light chain ratio in designation of myeloma-defining conditions and other diagnostic criteria based on serum free light chain assay. © American Society for Clinical Pathology 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  monoclonal gammopathy of undetermined significance; multiple myeloma; myeloma-defining condition; neoplastic monoclonal gammopathic manifestation; plasma-cell myeloma; serum free light chains; smoldering multiple myeloma

Mesh:

Substances:

Year:  2019        PMID: 30957173     DOI: 10.1093/labmed/lmz007

Source DB:  PubMed          Journal:  Lab Med        ISSN: 0007-5027


  2 in total

1.  Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains.

Authors:  Dorian Wilhite; Ahmed Arfa; Thomas Cotter; Natasha M Savage; Roni J Bollag; Gurmukh Singh
Journal:  Pract Lab Med       Date:  2021-10-12

2.  Evaluation of Free Light Chains (FLCs) Synthesis in Response to Exposure to SARS-CoV-2.

Authors:  Monika Gudowska-Sawczuk; Anna Moniuszko-Malinowska; Sara Pączek; Katarzyna Guziejko; Monika Chorąży; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.